Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors
NCT03326258Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Apr 2018
- Primary completion
- Apr 2018
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of glembatumumab vedotin in solid tumor (advanced stage), triple-negative breast cancer (TNBC), melanoma, Uveal melanoma (UM), sponsored by National Cancer Institute. Planned start Apr 2018; status: withdrawn.
02
Drugs
glembatumumab vedotin
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)melanomaUveal melanoma (UM)
Beyond the preview
Go deeper on NCT03326258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03326258.